Comparative Pharmacology
Head-to-head clinical analysis: FLAXEDIL versus PAVULON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAXEDIL versus PAVULON.
FLAXEDIL vs PAVULON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAXEDIL (gallamine triethiodide) is a nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, preventing muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
0.08-0.12 mg/kg IV bolus for neuromuscular blockade; additional doses of 0.01-0.02 mg/kg as needed.
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
None Documented
None Documented
The terminal elimination half-life of gallamine is approximately 2-4 hours in patients with normal renal function. This half-life is inversely related to creatinine clearance, and may be prolonged to 12-24 hours or more in patients with renal impairment, leading to cumulative effects and prolonged neuromuscular blockade.
Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment.
Flaxedil (gallamine triethiodide) is excreted primarily unchanged by the kidneys via glomerular filtration. Approximately 90-95% of an administered dose is eliminated in urine within 24 hours, with the remainder excreted in feces (<5%) via biliary elimination.
Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent